Glenmark readies scale up in the respiratory segment, with Ryaltris set for a US debut and a filing for a generic rival to Flovent anticipated. Running a facility in that market, though, is not an easy task, says the firm's leadership.

Glenmark readies scale up in the respiratory segment, with Ryaltris set for a US debut and a filing for a generic rival to Flovent anticipated. Running a facility in that market, though, is not an easy task, says the firm's leadership.

Canada-based biotech firm SaNOtize and Lupin battle it out in court over alleged breach of confidentiality and copyright infringement in a case concerning their nitric oxide nasal spray for COVID-19.

Glenmark's partnered nitric oxide nasal spray for COVID-19 debuts in India at about $11, with the firm spotlighting the reduction in viral load with the product and potential to cut the chain of transmission. But more competition appears to be in the wings.